Fluidigm

Under the terms of the deal, Fluidigm has the right to commercialize the CFTR sample prep assay for research use on its Juno automated microfluidic system.

The company announced this week the sale of 9,090,909 shares of common stock, which it expects will raise proceeds of roughly $30 million before expenses.

Revenues for the quarter were $23.9 million compared to $28.2 million the year before, driven largely by a decline in the company's genomics business.

Ascendas will develop and commercialize molecular diagnostic systems and assays using certain of Fluidigm's microfluidic technologies.

The South San Francisco, California-based single-cell biology firm brought in $25.5 million compared to $29.0 million in the first quarter of 2016.

Specialized single-cell "cores" are popping up to help scientists get the most out of new technologies.

The firm's full-year 2016 revenues fell 9 percent, also on lower instrument sales.

The firm reported preliminary declining revenues for both the fourth quarter and full-year 2016 reporting periods. 

The GenomeWeb Index stayed relatively flat in November, underperforming the Dow and Nasdaq for a second month in a row.

The partners have opened a new biorepository that will engage with clinical researchers and foster future personalized medicine efforts in the German capital.

Pages

Jay Shendure and his colleagues have developed a new method to more comprehensively identify human cell types, the NY Times reports.

Researchers in the UK and Japan have shown that infertility in mice with three sex chromosomes can be overcome, according to the Guardian.

China is embracing preimplantation genetic diagnosis, Nature News reports. 

In PLOS this week: host genetic factors associated with cervical neoplasia progression, population patterns for an ancient flowering rainforest plant, and more.